

Please amend claims 16-22 as follows:

16. (Amended) The method according to any of claims 1-14 or 15 wherein said exendin is exendin-

3.

17. (Amended) The method according to any of claims 1-14 or 15 wherein said exendin is exendin-

4.

18. (Amended) The method according to any of claims 1-14 or 15 wherein said exendin agonist is selected from the group consisting of exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, ¹⁴Leu, ²⁵Phe exendin-4 amide, ¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide, and ¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide.

19. (Amended) The method according to any of claims 1-14 or 15, further comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.

20. (Amended) The method according to any of claims 1-14 or 15 wherein said exendin agonist is an exendin agonist according to Formula I.

21. (Amended) The method according to any of claims 1-14 or 15 wherein said exendin agonist is an exendin agonist according to Formula II.

22. (Amended) The method according to any of claims 1-14 or 15 wherein said exendin agonist is an exendin agonist according to Formula III.

Please introduce the following new claims:

32. (New) The method according to any of claims 1-14 or 15 wherein said exendin agonist is an exendin agonist according to Formula II, and wherein said method further comprises administering to said subject a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.

33. (New) The method according to any of claims 1-14 or 15 wherein said exendin agonist is an exendin agonist according to Formula III, and wherein said method further comprises administering to said subject a therapeutically effective amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.

34. (New) The pharmaceutical composition according to any of claims 23-27 or 28, further comprising a therapeutically effect amount of one or more compounds selected from the group consisting of an amylin agonist, a leptin, and a CCK.

Remarks

Claims 1-31 are pending and indicated by the Examiner to be "free from the art," and there are no rejections of claims for any reason related to patentability. Office Action, Paper 11, May 1, 2001, page 2, ¶ 3.

Claims 1-15 and 23-30 are allowed. Claims 16-22 and 31 are objected to under 37 CFR 1.75 for allegedly being in multiple dependent format without referring to claims in the alternative. Claims 16-22 have been amended to confirm that they refer to previous claims in the alternative.